



Date: 06.05.2025

KEI Industries Limited

Registered and Corporate Office: D-90, Okhla Industrial Area, Phase-1, New Delhi- 110020 CIN: L74899DL1992PLC051527 Tel.: +91-11-26818840/8642/0242, Email: info@kei-ind.com Website: www.kei-ind.com

KEI/BSE/2025-26 The General Manager, Listing Operation, **BSE Limited,** 25th Floor, Phiroze Jeejeebhov Towers, Dalal Street, Fort, Mumbai- 400 001.

Sub: Monitoring Agency Report for the quarter ended March 31, 2025

Dear Sir / Madam,

Pursuant to the Regulation 32(6) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Regulation 173A of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, enclosed herewith is the Monitoring Agency Report for the quarter ended March 31, 2025 issued by CARE Ratings Limited, Monitoring Agency for the utilisation of the proceeds raised through Qualified Institutions Placement. The Monitoring Agency Report has been duly reviewed and taken on record by the Audit Committee & the Board of Directors of the Company in their meeting held on May 06, 2025.

The aforesaid information is also being made available on the website of the Company at https://www.kei-ind.com/

This is for your information and record.

Thanking You Yours truly, For KEI INDUSTRIES LIMITED

(KISHORE KUNAL) **VP (CORPORATE FINANCE) & COMPANY SECRETARY** FCS No.: 9429

CC:

Offices

The National Stock Exchange of India Ltd. Listing Division, Exchange Plaza, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (E), Mumbai -400 051

The Calcutta Stock Exchange Ltd. The Senior Manager, Listing Division, 7, Lyons Range, Kolkata-700001

Works-I : Bhiwadi : SP-919/920/922, RIICO Industrial Area, Phase-III, Bhiwadi, Dist. Alwar-301019 (Rajasthan); Tel : 01493-220106/221731, E-mail: bhiwadi@kei-ind.com Works-II: Chopanki: A-280-284 RIICO Industrial Area (Chopanki) Dist. Alwar-301019 (Rajasthan); E-mail: chopanki@kei-ind.com Works-III: Silvassa: 99/2/7, Madhuban Industrial Estate, Rakholi, Silvassa UT of Dadra & Nagar Haveli and Daman & Diu-396230;

Tel: +91-7359344404/7359244404; E-mail: silvassa@kei-ind.com

F-90/1-A, F Block, Okhla Industrial Area, Phase-1, New Delhi - 110020, Tel.: +91 11 6905 6800 Delhi Branch

Chennai : No.04, (Old No.23) SIR C P Ramasamy Road, 2nd Floor, Near Apollo Spectra Hospital, Alwarpet, Chennai-600018; Tel : 044-42009120 Kolkata : Arihanth Benchmark, 4th Floor, 113-F. Matheshwartola Road, Kolkata-700046. Tele: 033-40620820/40620821: E-mail: kolkata@kei-ind.com

Nirvan Corporate, 7th Floor, Opposite Aghadi Nagar, Pump House, Jijamata Road, Andheri East, Mumbai-400093; Tel: 91-22-28239673/28375642 Mumbai

E-mail: mumbai@kei-ind.com



No. CARE/NRO/GEN/2025-26/1007

Monitoring Agency Report

The Board of Directors

KEI industries Limited D-90, Okhla Industrial Area Phase-I, New Delhi-110020, India

May 06, 2025

Dear Sir/Mam,

Monitoring Agency Report for the quarter ended March 31, 2025 - in relation to the QIP of KEI Industries Limited("the Company")

We write in our capacity of Monitoring Agency for the Qualified institutional placement for the amount aggregating to Rs. 2,000.00 crore of the Company and refer to our duties cast under 173A of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations.

In this connection, we are enclosing the Monitoring Agency Report for the quarter ended March 31, 2025 as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated November 25th, 2024.

Request you to kindly take the same on records.

Thanking you,

Yours faithfully,

Anant Agarwal

Associate Director

anant.agarwal@careedge.in

Anant Agarwal



Report of the Monitoring Agency

Name of the issuer: KEI Industries Limited

For quarter ended: March 31, 2025

Name of the Monitoring Agency: CARE Ratings Limited

(a) Deviation from the objects: Nil

(b) Range of Deviation: Nil

Declaration:

We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an 'expert' as defined under Section 2(38) of the Companies Act, 2013.

The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity.

We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.

Signature:

Name and designation of the Authorized Signatory: Anant Agarwal Designation of Authorized person/Signing Authority: Associate Director

Anant Agarwal

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East),



1) Issuer Details:

Name of the issuer : KEI Industries Limited

Name of the promoters : Mr. Anil Gupta & Mrs. Archana Gupta

Industry/sector to which it belongs : Wires & Cables

2) Issue Details

Issue Period : 25th November 2024 to 28th November 2024, Date of allotment: 28th November 2024

: Qualified Institutional Placement Type of issue

Type of specified securities : Equity shares IPO Grading, if any : Not applicable Issue size (in `crore) : Rs. 2,000.00 crore

1) Details of the arrangement made to ensure the monitoring of issue proceeds:

Particulars	Reply	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments of the Board of Directors
Whether all utilization is as per the disclosures in the Offer Document?	No	CA certificate*, Bank statements, Placement document	Refer Note 1	No Comments
Whether shareholder approval has been obtained in case of material deviations# from expenditures disclosed in the Offer Document?	Not applicable	Not applicable	Not applicable	No Comments
Whether the means of finance for the disclosed objects of the issue have changed?	No	Confirmation from management	Nil	No Comments
Is there any major deviation observed over the earlier monitoring agency reports?	No	Monitoring agency report	No deviation in earlier monitoring agency report	No Comments
Whether all Government/statutory approvals related to the object(s) have been obtained?	All material approvals taken. Further approvals to be taken when need arises	Placement Document	Nil	No Comments
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	Not applicable	Not applicable	Not applicable	No Comments

CARE Ratings Limited 9th floor, C-001/A2, Berger Towers, Sector 16B, Noida,

Gautam Budh Nagar, Uttar Pradesh -201301

Phone: +91-120-4452000

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai - 400 022

Phone: +91-22-6754 3456



Particulars	Reply	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments of the Board of Directors
Are there any favorable/unfavorable events affecting the viability of these object(s)?	No	Confirmation from	Nil	No Comments
Is there any other relevant information that may materially affect the decision making of the investors?	No	management (Refer Note 1)	Nil	No Comments

^{*}CA certificate from Pawan Shubham & Co. (statutory auditor) dated April 23, 2025

#Where material deviation may be defined to mean:

b) Deviation in the amount of funds actually utilized by more than 10% of the amount projected in the offer documents.

Note 1: In fiscal 2025, the funds incurred towards Sanand capital expenditure and general corporate purposes fell short of the amount specified in the placement document. As per the company's management, the reason for low utilization was mainly because of the estimation of project expenses and the corresponding payment schedule was prepared prior to the receipt of QIP Funds. However, given the complex nature of the project under construction i.e the building and design of plant and machinery, revisions were made to the original drawings and designs. As a result, delivery schedule for plant & machinery and building construction has been extended by few months, causing a shift in certain payments, which will now be made in FY26 as permitted under placement documents. Additionally technical viability remains on track for completion as per the management.

Further, As per the placement document, if the Net Proceeds are not utilized (in full or in part) for the Objects of the Issue during the period stated due to any reason, including (i) the timing of completion of the Issue; (ii) market conditions outside the control of our Company; and (iii) any other economic, business and commercial considerations, the remaining Net Proceeds shall be utilized in subsequent periods in such manner as may be determined by the company, in accordance with applicable laws.

9th floor, C-001/A2, Berger Towers, Sector 16B, Noida,

Gautam Budh Nagar, Uttar Pradesh -201301 Phone: +91-120-4452000

F11011e. 131-120-4432000

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East),

Mumbai - 400 022 Phone: +91-22-6754 3456

a) Deviation in the objects or purposes for which the funds have been raised



2) Details of objects to be monitored:

(i) Cost of objects -

		Source of information /	Original cost			Comments of the Board of Directors		
Sr. No	Item Head	certifications considered by Monitoring Agency for preparation of report	(as per the Offer Document) in Rs. Crore	Revised Cost in Rs. Crore	Comments of the Monitoring Agency	Reason for cost revision	Proposed financing option	Particulars of -firm arrangements made
1	Partial funding for setting up a cable manufacturing facility at Sanand, Ahmedabad.	Chartered Accountant certificate*, Placement Document	1450.00	NA	NA	No Comments	No Comments	No Comments
2	Repayment/ pre-payment, in part or in full, of certain outstanding borrowings availed by the company	Chartered Accountant certificate*, Placement Document	275.99	NA	NA	No Comments	No Comments	No Comments
3	General Corporate Purpose	Chartered Accountant certificate*, Placement Document	239.64	NA	NA	No Comments	No Comments	No Comments
4	Issue related expenses	Chartered Accountant certificate*, Placement Document	34.37	NA	NA	No Comments	No Comments	No Comments
Total			2,000.00					

^{*} Chartered Accountant certificates from Pawan Shubham & Co. (statutory auditor) dated April 23, 2025.



(ii) Progress in the objects -

		Source of information	Amount as proposed Amount utilised			Rs. Crore	Unutilised amount in Rs. crore	Comments of the Monitoring Agency		nts of the Directors
Sr. No	Item Head	/ certifications considered by Monitoring Agency for preparation of report	in the Offer Document in Rs. Crore	As at beginning of the quarter in Rs. Crore	During the quarter in Rs. Crore	At the end of the quarter in Rs. Crore			Reasons for idle funds	Proposed course of action
1	Partial funding for setting up a cable manufacturing facility at Sanand, Ahmedabad.	Chartered Accountant certificate*, Bank Statements, Placement Document	1450.00	32.81	128.60	161.41	1,288.59	Rs. 621.03 crore was utilized towards the said purposes till March 31, 2025.	No Comments	No Comments
2	Repayment/ pre- payment, in part or in full, of certain outstanding borrowings availed by the company	Chartered Accountant certificate*, Bank Statements, Placement Document	275.99	183.62	92.37	275.99	0.00	Balance Rs. 1378.97 crore was lying in FDR's and in Monitoring account.	No Comments	No Comments
3	General Corporate Purpose	Chartered Accountant certificate*, Bank Statements, Placement Document	239.64	0.00	149.26	149.26	90.38		No Comments	No Comments
4	Issue related expenses#	Chartered Accountant certificate*, Bank Statements, Placement Document	34.37	30.86	3.51	34.37	0.00		No Comments	No Comments
Tota			2,000.00	247.29	373.74	621.03	1,378.97			

^{*}Chartered Accountant certificates from Pawan Shubham & Co. (statutory auditor) dated April 23, 2025

CARE Ratings Limited 9th floor, C-001/A2, Berger Towers, Sector 16B, Noida,

Gautam Budh Nagar, Uttar Pradesh -201301

Phone: +91-120-4452000

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai - 400 022

Phone: +91-22-6754 3456

[#] Company has incurred Rs. 0.99 crore of QIP expenses from internal account in Q3FY25 and reimbursed the same from QIP Monitoring account in Q4FY25.



(iii) Deployment of unutilized OIP proceeds:

Sr.	Type of instrument and name of the entity	Amount invested*	Maturity data	Forning	Return on	Market Value as at the
No.	invested in	(Rs. Crore)	Maturity date	Earning	Investment (%)	end of quarter
1.	FDR (Axis)	30.00	19-10-2025	0.72	7.25	NA
2.	FDR (Axis)	30.00	28-10-2025	0.72	7.25	NA
3.	FDR (Axis)	30.00	04-11-2025	0.72	7.25	NA
4.	FDR (Axis)	30.00	11-11-2025	0.72	7.25	NA
5.	FDR (Axis)	25.00	17-12-2025	0.59	7.50	NA
6.	FDR (Axis)	25.00	21-12-2025	0.59	7.50	NA
7.	FDR (Axis)	25.00	26-11-2025	0.56	7.25	NA
8.	FDR (Axis)	25.00	03-12-2025	0.56	7.25	NA
9.	FDR (Axis)	25.00	10-12-2025	0.56	7.25	NA
10.	FDR (Axis)	25.00	28-12-2025	0.57	7.40	NA
11.	FDR (Axis)	25.00	05-01-2026	0.57	7.40	NA
12.	FDR (Axis)	30.00	14-01-2026	0.52	7.51	NA
13.	FDR (Axis)	30.00	03-02-2026	0.39	7.40	NA
14.	FDR (Axis)	26.00	11-02-2026	0.30	7.50	NA
15.	FDR (Axis)	25.00	17-02-2026	0.25	7.45	NA
16.	FDR (Axis)	10.00	24-02-2026	0.09	7.45	NA
17.	FDR (Axis)	25.00	04-03-2026	0.17	7.45	NA
18.	FDR (Axis)	3.10	05-04-2025	0.02	5.75	NA
19.	FDR (Axis)	30.00	12-05-2025	0.11	6.50	NA
20.	FDR (BOB)	25.00	06-08-2025	0.54	7.00	NA
21.	FDR (BOB)	25.00	13-08-2025	0.54	7.00	NA
22.	FDR (BOB)	30.00	20-08-2025	0.65	7.00	NA
23.	FDR (BOB)	30.00	27-08-2025	0.65	7.00	NA
24.	FDR (BOB)	30.00	05-09-2025	0.65	7.00	NA
25.	FDR (BOB)	30.00	12-09-2025	0.67	7.25	NA
26.	FDR (BOB)	30.00	19-09-2025	0.67	7.25	NA
27.	FDR (BOB)	30.00	26-09-2025	0.67	7.25	NA
28.	FDR (BOB)	20.00	04-10-2025	0.45	7.25	NA
29.	FDR (DCB)	30.00	28-05-2025	0.74	7.65	NA

CARE Ratings Limited 9th floor, C-001/A2, Berger Towers, Sector 16B, Noida,

Gautam Budh Nagar, Uttar Pradesh -201301

Phone: +91-120-4452000

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East),

Mumbai - 400 022 Phone: +91-22-6754 3456



	Total	1,385.06#		28.75		
51.	Balance in Monitoring Account	0.23	NA	NA	NA	NA
50.	FDR (Yes Bank)	30.00	16-04-2025	0.71	7.35	NA
49.	FDR (Yes Bank)	30.00	09-04-2025	0.71	7.35	NA
48.	FDR (Yes Bank)	30.00	04-04-2025	0.71	7.35	NA
47.	FDR (Union)	20.00	13-08-2025	0.46	7.35	NA
46.	FDR (Union)	30.00	03-08-2025	0.68	7.35	NA
45.	FDR (Union)	30.00	27-07-2025	0.68	7.35	NA
44.	FDR (Union)	30.00	19-07-2025	0.68	7.35	NA
43.	FDR (Union)	30.00	11-07-2025	0.68	7.35	NA
42.	FDR (Union)	30.00	04-07-2025	0.68	7.35	NA
41.	FDR (Union)	30.00	27-06-2025	0.68	7.35	NA
40.	FDR (SBI)	30.46	29-04-2025	0.10	6.25	NA
39.	FDR (SBI)	20.27	21-04-2025	0.09	6.25	NA
38.	FDR (IndusInd)	30.00	21-05-2025	0.71	7.35	NA
37.	FDR (Indusind)	30.00	14-05-2025	0.71	7.35	NA
36.	FDR (IDBI)	35.00	17-06-2025	0.83	7.26	NA
35.	FDR (IDBI)	35.00	10-06-2025	0.83	7.26	NA
34.	FDR (ICICI)	35.00	07-05-2025	0.79	6.95	NA
33.	FDR (ICICI)	35.00	30-04-2025	0.79	6.95	NA
32.	FDR (ICICI)	30.00	23-04-2025	0.67	6.95	NA
31.	FDR (DCB)	30.00	07-06-2025	0.79	8.00	NA
30.	FDR (DCB)	30.00	07-06-2025	0.79	8.00	NA

^{*}As per CA certificate from Pawan Shubham & Co. (Statutory Auditor) dated April 23, 2025.

#Includes total interest on FDR of Rs. 6.09 crore. Of this, Rs. 5.36 crore (net of TDS) was received in the monitoring account and subsequently redeployed in FDR, while Rs. 0.73 crore of interest was directly rolled over into new FDRs. Unutilised proceeds out of QIP is 1,378.97 crore.

Bifurcation of Interest included in Unutilised proceeds

Particular	Amount (Rs. Crore)
Interest received (net of TDS) in Q3FY25	0.89
Interest received (net of TDS) in Q4FY25	4.47

CARE Ratings Limited 9th floor, C-001/A2, Berger Towers, Sector 16B, Noida,

Gautam Budh Nagar, Uttar Pradesh -201301

Phone: +91-120-4452000

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai - 400 022

Phone: +91-22-6754 3456

Email: care@careedge.in • www.careedge.in

CIN-L67190MH1993PLC071691



Interest directly rolled over to new FDR's	0.73
Total Interest included in Unutilized proceeds	6.09

(iv) Delay in implementation of the object(s) –

	Completion Date			Comments of the Board of Directors		
Objects	Objects As per the offer document Actual Delay (no. of days/ months)		Delay (no. of days/ months)	Reason of delay	Proposed course of action	
Partial funding for setting up a cable manufacturing facility at Sanand, Ahmedabad.	Rs. 849.01 crore in Fiscal 2025 and balance in Fiscal 2026	In Progress, Rs. 161.41 crore incurred in Fiscal 2025	Ongoing, Refer Note 1	No Comments	No Comments	
Repayment/ pre-payment, in part or in full, of certain outstanding borrowings availed by the company	Entire amount by Fiscal 2025	Completed in Fiscal 2025	No delays	No Comments	No Comments	
General Corporate Purpose	Rs. 150.00 crore in Fiscal 2025 and balance in Fiscal 2026	In Progress, Rs. 149.26 crore incurred in Fiscal 2025	Ongoing, Refer Note 1	No Comments	No Comments	
Issue related expenses	NA	NA	NA	No Comments	No Comments	

Note 1: In fiscal 2025, the funds incurred towards Sanand capital expenditure and general corporate purposes fell short of the amount specified in the placement document. As per the company` management, the reason for low utilization was mainly because of the estimation of project expenses and the corresponding payment schedule was prepared prior to the receipt of QIP Funds. However, given the complex nature of the project under construction i.e the building and design of plant and machinery, revisions were made to the original drawings and designs. As a result, delivery schedule for plant & machinery and building construction has been extended by few months, causing a shift in certain payments, which will now be made in FY26 as permitted under placement documents. Additionally technical viability remains on track for completion as per the management.

Further, As per the placement document, if the Net Proceeds are not utilized (in full or in part) for the Objects of the Issue during the period stated due to any reason, including (i) the timing of completion of the Issue; (ii) market conditions outside the control of our Company; and (iii) any other economic, business and commercial considerations, the remaining Net Proceeds shall be utilized in subsequent periods in such manner as may be determined by the company, in accordance with applicable laws.

9th floor, C-001/A2, Berger Towers, Sector 16B, Noida, Gautam Budh Nagar, Uttar Pradesh -201301

Phone: +91-120-4452000

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai - 400 022

Phone: +91-22-6754 3456



3) Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document:

Sr. No	Item Head^	Amount in Rs. Crore	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of Monitoring Agency	Comments of the Board of Directors
1	Purchase of Raw Material	147.39	CA Certificate*, Bank Statements	Incurred Rs. 149.26 crore during	No Comments
2.	Inspection, Testing of Wires & Cables	1.87	CA Certificate*, Bank Statements	the quarter towards purchase of raw material and testing of wires & Cables	No Comments
	Total	149.26			

^{*}CA certificate from Pawan Shubham & Co. dated April 23, 2025

9th floor, C-001/A2, Berger Towers, Sector 16B, Noida, Gautam Budh Nagar, Uttar Pradesh -201301

Phone: +91-120-4452000

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai - 400 022

Phone: +91-22-6754 3456

[^] Section from the offer document related to GCP: Company proposes to deploy ₹ 239.64 crore out of the Net Proceeds towards general corporate purposes of our Company, subject to the amount allocated towards general corporate purpose not exceeding 25% of the Gross Proceeds, in compliance with the circular bearing reference no. NSE/ CML/2022/56 dated December 13, 2022, issued by NSE and circular no. 20221213-47 dated December 13, 2022, issued by BSE. Such general corporate purposes of our Company may include, but are not restricted to, funding growth opportunities, business development initiatives, supporting our Company's working capital requirements, meeting expenses incurred in ordinary course of business, making payments to vendors and towards any exigencies or any other purpose, as may be approved by our Board or a duly constituted committee thereof, subject to compliance with applicable law, including provisions of the Companies Act.



Disclaimers to MA report:

a) This Report is prepared by CARE Ratings Ltd (hereinafter referred to as "Monitoring

Agency/MA"). The MA has taken utmost care to ensure accuracy and objectivity while developing

this Report based on the information provided by the Issuer and information obtained from sources

believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute

the opinion of MA to deal in any security of the Issuer in any manner whatsoever.

b) This Report has to be seen in its entirety; the selective review of portions of the Report may lead to

inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided

by the management /officials/ consultants of the Issuer and third-party sources like statutory auditors

(or from peer reviewed CA firms) appointed by the Issuer believed by it to be accurate and reliable.

c) Nothing contained in this Report is capable or intended to create any legally binding obligations on

the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said

information. The MA is also not responsible for any errors in transmission and specifically states that

it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.

d) The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an

expert to the extent defined under Section 2(38) of the Companies Act, 2013. While the MA has

obtained information from sources it believes to be reliable, it does not perform an audit and

undertakes no independent verification of any information/ certifications/ statements it receives from

auditors (or from peer reviewed CA firms), lawyers, chartered engineers or other experts, and relies

on in its reports.

e) The MA or its affiliates may have other commercial transactions with the entity to which the report

pertains. As an example, the MA may rate the issuer or any debt instruments / facilities issued or

proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate

compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters

of the instruments, facilities, securities or from obligors.

4th Floor, Godrej Coliseum, Somaiya Hospital